Log In
BCIQ
Print this Print this
 

XmAb13676

  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionBispecific antibody against CD20 and CD3
Molecular Target CD20 ; CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationB cell lymphoma
Indication DetailsTreat CD20-positive B cell malignancies
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,550.0M

$150.0M

$2,400.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/28/2016

$2,550.0M

$150.0M

$2,400.0M

Get a free BioCentury trial today